ライフサイエンスコーパス: bioartificial

1 We created a bioartificial adrenal with 3D cell culture conditions by

2 In conclusion, transplantation of a bioartificial adrenal with xenogeneic cells may be a tre

3 To mimic the 3D context of human arteries, bioartificial arteries were engineered from collagen typ

4 r advances will need to be made before these bioartificial devices can be considered for routine appl

5 stem-cell research, tissue engineering, and bioartificial devices for the treatment of the heterogen

6 n, multiagent immunosuppressant therapy, and bioartificial devices such as lacrimal gland microdevice

7 In this bioartificial endocrine pancreas, the hardware will be r

8 acturing of a regenerative medicine-inspired bioartificial endocrine pancreas.

9 ion of a new-generation, fully human-derived bioartificial endocrine pancreas.

10 Bioartificial grafts that provide gas exchange have been

11 A bioartificial heart is a theoretical alternative to tran

12 Generating a bioartificial heart requires engineering of cardiac arch

13 We engineered polyethylene glycol-based bioartificial hydrogel matrices presenting protease-degr

14 The bioartificial kidney (BAK) consists of a conventional he

15 To assess the effect of the bioartificial kidney and the RAD in septic shock, pigs w

16 l replacement therapy in a tissue-engineered bioartificial kidney comprising both biologic and synthe

17 The development of a tissue-engineered bioartificial kidney consisting of a conventional hemofi

18 herapeutic approach with a tissue-engineered bioartificial kidney may be a new treatment modality for

19 s, continuous renal replacement therapy, the bioartificial kidney, and peritoneal dialysis in the man

20 The bioartificial kidney, combining hemofiltration with a de

21 We have developed a novel bioartificial liver (BAL) composed of porcine hepatocyte

22 from lymphocytes of patients treated with a bioartificial liver (BAL) containing pig hepatocytes and

23 The purpose of this study was to develop a bioartificial liver (BAL) to treat patients with severe

24 s an extracorporeal porcine hepatocyte-based bioartificial liver (BAL).

25 dy source of metabolic function for use in a bioartificial liver (BAL).

26 to pig hepatocytes after treatment with the bioartificial liver (BAL).

27 The BioArtificial liver (UCLBAL) improved important prognost

28 art of an extracorporeal system, such as the bioartificial liver assist device, or an implantable tis

29 This is a key advance in bioartificial liver development.

30 corporating the hepatocyte-like cells into a bioartificial liver device to treat fulminant hepatic fa

31 limitations of novel technologies including bioartificial liver devices and auxiliary liver transpla

32 This has prompted the design of bioartificial liver devices to "bridge" patients until t

33 l hepatology and cell-based therapies (e.g., bioartificial liver devices).

34 ion of cryopreserved isolated hepatocytes in bioartificial liver devices.

35 therapies for liver disorders or for use in bioartificial liver devices.

36 ned, implemented and tested a clinical-scale BioArtificial Liver machine containing a biomass derived

37 A BioArtificial Liver machine could temporarily replace th

38 heroids appear suitable for application in a bioartificial liver or as an in vitro liver tissue const

39 Extracorporeal bioartificial liver support devices remain an exciting b

40 Advances in the field of bioartificial liver support have led to an increasing de

41 ck, neither of which is likely to respond to bioartificial liver support or treatment with convention

42 olved in a phase I/II clinical trial using a bioartificial liver support system (BLSS), we proceeded

43 Artificial and bioartificial liver support systems have thus far not de

44 atocyte cocultures, typically extracorporeal bioartificial liver support systems, are reviewed in the

45 ttempted by various approaches, for example, bioartificial liver support, extracorporeal pig liver pe

46 ll research may allow provision of cells for bioartificial liver support.

47 particularly for cell therapeutics including bioartificial liver systems (BALs).

48 he risk of viral exposure to patients during bioartificial liver therapy.

49 low fiber membranes, such as those used in a bioartificial liver, block the transfer of PERV.

50 Over the years, the development of bioartificial liver-assist devices has aimed at replacin

51 ery, and therapeutic applications, such as a bioartificial liver.

52 ause of the potential to use these cells for bioartificial livers, as a vehicle for gene transfer, an

53 Looking ahead, current challenges in bioartificial lung engineering include creation of ideal

54 , current challenges and ongoing research in bioartificial lung engineering.

55 Engineering bioartificial lung grafts from patient-derived cells cou

56 Creation of a bioartificial lung requires engineering of viable lung a

57 esults support the application of engineered bioartificial matrices to promote vascularization for di

58 althy hematopoietic progenitor cells (HPCs), bioartificial matrixes from rat tail or purified human c

59 Here we show that HLOs required a bioartificial microporous poly(lactide-co-glycolide) (PL

60 thod for delivery of rVEGF using implantable bioartificial muscle (BAM) tissues made from genetically

61 al applications in biocompatibility studies, bioartificial muscle engineering, skeletal muscle differ

62 e centimeter large, few hundred micron-thick bioartificial muscle tissues composed of viable, dense,

63 tal muscle cells were tissue engineered into bioartificial muscles and flown in perfusion bioreactors

64 tive to allotransplantation, patient-derived bioartificial myocardium could provide functional suppor

65 into biomaterials has engendered the use of bioartificial nerve conduits as an alternative to autolo

66 ing the rate and extent of regeneration, the bioartificial nerve graft holds great promise for improv

67 c advances leading to the development of the bioartificial nerve graft.

68 ish the biosafety of this device and related bioartificial organ systems, these analyses support the

69 metabolic responses in several microfluidic bioartificial organs (liver, kidney, and cocultures), as

70 Microfluidic bioartificial organs enable the spatial and temporal con

71 ors, diagnostic devices, catalysts, and even bioartificial organs.

72 Glycemic efficacy of a bioartificial pancreas based on insulin-secreting entero

73 afe transplantation of porcine islets with a bioartificial pancreas device in diabetic primates witho

74 A desirable bioartificial pancreas should be easy to implant, biopsy

75 Implantation of bioartificial patches distorts myocardial geometry, and

76 Although bioartificial support systems are under active investiga

77 With the liquid bioartificial tissue compound used in this study, we ach

78 Injectable bioartificial tissue restores the heart's geometry and f

79 e for the design and in vitro cultivation of bioartificial tissues, we have developed a multiscale co

80 lantation survival of thick, prevascularized bioartificial tissues.